Low-Frequency Electroacupuncture Trial for Diabetic Peripheral Neuropathy
ClinicalTrials.gov Studies
Summary
A prospective, randomized, sham-controlled clinical trial has been registered on ClinicalTrials.gov to evaluate the efficacy and potential mechanisms of low-frequency (2 Hz) electroacupuncture in patients with diabetic peripheral neuropathy (DPN). The study will assign participants to either a verum 2 Hz EA group or a sham EA group and assess nerve conduction velocity, pain intensity, serum neurotrophic factors and inflammatory cytokines, and quality of life. The trial aims to provide clinical evidence on whether low-frequency electroacupuncture effects are related to neurotrophic and inflammatory pathways.
“Diabetic peripheral neuropathy (DPN) is a common and disabling complication of diabetes.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new clinical trial registration for NCT07551726 has been posted to ClinicalTrials.gov, describing a randomized, sham-controlled study investigating low-frequency electroacupuncture (2 Hz) for diabetic peripheral neuropathy. The trial will enroll participants assigned to verum or sham EA groups, measuring nerve conduction velocity, pain intensity, neurotrophic factors, inflammatory cytokines, and quality of life outcomes.
Clinical investigators conducting trials on peripheral neuropathy interventions should ensure their ongoing studies are properly registered and consistent with emerging evidence from this trial upon completion. Sponsors of similar DPN studies may wish to monitor results for implications on study design and endpoints.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Effect of Low-Frequency Electroacupuncture on Diabetic Peripheral Neuropathy
N/A NCT07551726 Kind: NA Apr 27, 2026
Abstract
Diabetic peripheral neuropathy (DPN) is a common and disabling complication of diabetes. Many patients experience pain, numbness, and impaired quality of life, while currently available treatments may have limited benefit or cause adverse effects. Electroacupuncture (EA) may provide a safe, non-pharmacological treatment option, but further clinical evidence is needed.
The purpose of this study is to evaluate the efficacy and potential mechanisms of low-frequency (2 Hz) electroacupuncture in patients with DPN. In this prospective, randomized, sham-controlled trial, participants will be assigned to either a verum 2 Hz EA group or a sham EA group. The study will assess nerve conduction velocity, pain intensity, serum neurotrophic factors and inflammatory cytokines, and quality of life.
This study is intended to provide clinical evidence on the use of low-frequency EA for DPN and to examine whether its effects are related to neurotrophic and inflammatory pathways.
Conditions: Diabetic Peripheral Neuropathy (DPN), Electroacupuncture
Interventions: EA, Sham EA
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.